PPARA and metabolic dysfunction-associated steatohepatitis: In NASH condition led by PPAR-α antagonist disrupts the release of lipid regulatory genes, and pro-inflammatory and inflammatory cytokines from liver and gut tissue resulting in the deregulation of hepatic metabolism and phenotypic changes [6, 11].